Paul F. Kantor
Publications by Year
Research Areas
Congenital Heart Disease Studies, Cardiomyopathy and Myosin Studies, Cardiovascular Function and Risk Factors, Heart Failure Treatment and Management, Cardiac pacing and defibrillation studies
Most-Cited Works
- → 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary(2020)985 cited
- → The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase(2000)803 cited
- → 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy(2020)659 cited
- → Pediatric Cardiomyopathies(2017)292 cited
- → Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)(2018)276 cited
- → Presentation, Diagnosis, and Medical Management of Heart Failure in Children: Canadian Cardiovascular Society Guidelines(2013)257 cited
- → Reduction of ischemic K+ loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea.(1990)223 cited
- → Outcomes of Restrictive Cardiomyopathy in Childhood and the Influence of Phenotype(2012)220 cited